OBJECTIVE: Acute lung injury secondary to smoke inhalation is a major source of morbidity and mortality in burn patients. We tested the hypothesis that nebulized epinephrine would ameliorate pulmonary dysfunction secondary to acute lung injury by reducing airway hyperemia and edema formation and mediating bronchodilatation in an established, large animal model of inhalation injury. DESIGN: Prospective, controlled, randomized trial. SETTING: University research laboratory. SUBJECTS: Twenty-four chronically instrumented, adult, female sheep. INTERVENTIONS: Following baseline measurements, the animals were allocated to a sham-injured group (n = 5), an injured and saline-treated group (n = 6), or an injured group treated with 4 mg of nebulized epinephrine every 4 hrs (n = 6). Inhalation injury was induced by 48 breaths of cotton smoke. The dose of epinephrine was derived from dose finding experiments (n = 7 sheep). MEASUREMENTS AND MAIN RESULTS: The injury induced significant increases in airway blood flows, bronchial wet/dry weight ratio, airway obstruction scores, ventilatory pressures, and lung malondialdehyde content, and contributed to severe pulmonary dysfunction as evidenced by a significant decline in Pao₂/Fio₂ ratio and increase in pulmonary shunt fraction. Nebulization of epinephrine significantly reduced tracheal and main bronchial blood flows, ventilatory pressures, and lung malondialdehyde content. The treatment was further associated with significant improvements of Pao₂/FIO₂ ratio and pulmonary shunting. CONCLUSIONS: Nebulization of epinephrine reduces airway blood flow and attenuates pulmonary dysfunction in sheep subjected to severe smoke inhalation injury. Future studies will have to improve the understanding of the underlying pathomechanisms and identify the optimal dosing for the treatment of patients with this injury.
OBJECTIVE:Acute lung injury secondary to smoke inhalation is a major source of morbidity and mortality in burn patients. We tested the hypothesis that nebulized epinephrine would ameliorate pulmonary dysfunction secondary to acute lung injury by reducing airway hyperemia and edema formation and mediating bronchodilatation in an established, large animal model of inhalation injury. DESIGN: Prospective, controlled, randomized trial. SETTING: University research laboratory. SUBJECTS: Twenty-four chronically instrumented, adult, female sheep. INTERVENTIONS: Following baseline measurements, the animals were allocated to a sham-injured group (n = 5), an injured and saline-treated group (n = 6), or an injured group treated with 4 mg of nebulized epinephrine every 4 hrs (n = 6). Inhalation injury was induced by 48 breaths of cotton smoke. The dose of epinephrine was derived from dose finding experiments (n = 7 sheep). MEASUREMENTS AND MAIN RESULTS: The injury induced significant increases in airway blood flows, bronchial wet/dry weight ratio, airway obstruction scores, ventilatory pressures, and lung malondialdehyde content, and contributed to severe pulmonary dysfunction as evidenced by a significant decline in Pao₂/Fio₂ ratio and increase in pulmonary shunt fraction. Nebulization of epinephrine significantly reduced tracheal and main bronchial blood flows, ventilatory pressures, and lung malondialdehyde content. The treatment was further associated with significant improvements of Pao₂/FIO₂ ratio and pulmonary shunting. CONCLUSIONS: Nebulization of epinephrine reduces airway blood flow and attenuates pulmonary dysfunction in sheep subjected to severe smoke inhalation injury. Future studies will have to improve the understanding of the underlying pathomechanisms and identify the optimal dosing for the treatment of patients with this injury.
Authors: Katsumi Shimoda; Kazunori Murakami; Perenlei Enkhbaatar; Lillian D Traber; Robert A Cox; Hal K Hawkins; Frank C Schmalstieg; Katalin Komjati; Jon G Mabley; Csaba Szabo; Andrew L Salzman; Daniel L Traber Journal: Am J Physiol Lung Cell Mol Physiol Date: 2003-03-07 Impact factor: 5.464
Authors: Perenlei Enkhbaatar; Kazunori Murakami; Katsumi Shimoda; Akio Mizutani; Lillian Traber; Gary B Phillips; John F Parkinson; Robert Cox; Hal Hawkins; David Herndon; Daniel Traber Journal: Am J Respir Crit Care Med Date: 2003-04-01 Impact factor: 21.405
Authors: Robert A Cox; Ann S Burke; Kazutaka Soejima; Kazunori Murakami; Jiro Katahira; Lillian D Traber; David N Herndon; Frank C Schmalstieg; Daniel L Traber; Hal K Hawkins Journal: Am J Respir Cell Mol Biol Date: 2003-09 Impact factor: 6.914
Authors: Perenlei Enkhbaatar; Kazunori Murakami; Robert Cox; Martin Westphal; Naoki Morita; Kimberly Brantley; Ann Burke; Hal Hawkins; Frank Schmalstieg; Lillian Traber; David Herndon; Daniel Traber Journal: Shock Date: 2004-07 Impact factor: 3.454
Authors: Robert A Cox; Ron P Mlcak; David L Chinkes; Sam Jacob; Perenlei Enkhbaatar; Jesse Jaso; Lauren P Parish; Daniel L Traber; Marc G Jeschke; David N Herndon; Hal K Hawkins Journal: Shock Date: 2008-03 Impact factor: 3.454
Authors: Marc G Jeschke; Ronald P Mlcak; Celeste C Finnerty; William B Norbury; Gerd G Gauglitz; Gabriela A Kulp; David N Herndon Journal: Crit Care Date: 2007 Impact factor: 9.097
Authors: Matthias Lange; Csaba Szabo; Daniel L Traber; Eszter Horvath; Atsumori Hamahata; Yoshimitsu Nakano; Lillian D Traber; Robert A Cox; Frank C Schmalstieg; David N Herndon; Perenlei Enkhbaatar Journal: Shock Date: 2012-05 Impact factor: 3.454
Authors: Guillermo Foncerrada; Derek M Culnan; Karel D Capek; Sagrario González-Trejo; Janos Cambiaso-Daniel; Lee C Woodson; David N Herndon; Celeste C Finnerty; Jong O Lee Journal: Ann Plast Surg Date: 2018-03 Impact factor: 1.539
Authors: Guillermo Foncerrada; Francisco Lima; Robert P Clayton; Ronald P Mlcak; Perenlei Enkhbaatar; David N Herndon; Oscar E Suman Journal: J Burn Care Res Date: 2017 Nov/Dec Impact factor: 1.845
Authors: Margaret R Passmore; Yoke L Fung; Gabriela Simonova; Samuel R Foley; Sara D Diab; Kimble R Dunster; Michelle M Spanevello; Charles I McDonald; John-Paul Tung; Natalie M Pecheniuk; Karen Hay; Kiran Shekar; John F Fraser Journal: Crit Care Date: 2017-07-29 Impact factor: 9.097
Authors: Patrick F Walker; Michelle F Buehner; Leslie A Wood; Nathan L Boyer; Ian R Driscoll; Jonathan B Lundy; Leopoldo C Cancio; Kevin K Chung Journal: Crit Care Date: 2015-10-28 Impact factor: 9.097